X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (52) 52
index medicus (37) 37
egfr-targeted therapy (34) 34
oncology (34) 34
cancer (26) 26
animals (21) 21
egfr-targeted therapies (21) 21
egfr (20) 20
epidermal growth factor (19) 19
growth-factor receptor (19) 19
mutation (19) 19
colorectal cancer (18) 18
receptor, epidermal growth factor - antagonists & inhibitors (18) 18
epidermal growth factor receptor (17) 17
female (17) 17
acquired-resistance (15) 15
cetuximab (15) 15
cell biology (14) 14
cell line, tumor (14) 14
cell lung-cancer (13) 13
gefitinib (13) 13
pharmacology & pharmacy (13) 13
chemotherapy (12) 12
receptor, epidermal growth factor - genetics (12) 12
aged (11) 11
male (11) 11
middle aged (11) 11
erlotinib (10) 10
expression (10) 10
receptor, epidermal growth factor - metabolism (10) 10
1st-line treatment (9) 9
antineoplastic agents - pharmacology (9) 9
health aspects (9) 9
mice (9) 9
molecular targeted therapy (9) 9
adult (8) 8
egfr targeted therapy (8) 8
growth-factor-receptor (8) 8
immunohistochemistry (8) 8
kras (8) 8
prognosis (8) 8
therapy (8) 8
analysis (7) 7
antineoplastic agents - therapeutic use (7) 7
development and progression (7) 7
drug resistance (7) 7
lung-cancer (7) 7
monoclonal antibodies (7) 7
protein kinase inhibitors - pharmacology (7) 7
protein kinase inhibitors - therapeutic use (7) 7
proteins (7) 7
signal transduction (7) 7
signal transduction - drug effects (7) 7
tumors (7) 7
tyrosine (7) 7
care and treatment (6) 6
cell proliferation - drug effects (6) 6
colorectal neoplasms - drug therapy (6) 6
colorectal neoplasms - genetics (6) 6
colorectal neoplasms - pathology (6) 6
drug resistance, neoplasm (6) 6
epidermal-growth-factor (6) 6
erbb receptors - antagonists & inhibitors (6) 6
lung cancer (6) 6
lung cancer, non-small cell (6) 6
metastasis (6) 6
nanoparticles (6) 6
phase-ii trial (6) 6
phosphorylation (6) 6
resistance (6) 6
xenograft model antitumor assays (6) 6
adenocarcinoma - metabolism (5) 5
aged, 80 and over (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
apoptosis - drug effects (5) 5
article (5) 5
biochemistry & molecular biology (5) 5
cancer therapies (5) 5
carcinoma, non-small-cell lung - genetics (5) 5
cetuximab plus irinotecan (5) 5
colorectal-cancer (5) 5
epidermal growth factor receptors (5) 5
erbb receptors - genetics (5) 5
gene amplification (5) 5
gene expression regulation, neoplastic (5) 5
genetic aspects (5) 5
genotype (5) 5
glioblastoma (5) 5
hematology, oncology and palliative medicine (5) 5
in situ hybridization, fluorescence (5) 5
in-vitro (5) 5
k-ras (5) 5
kinases (5) 5
metastatic colorectal-cancer (5) 5
mutation - genetics (5) 5
mutations (5) 5
non-small cell lung cancer (5) 5
pancreatic cancer (5) 5
panitumumab (5) 5
pathology (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Cancer, ISSN 0007-0920, 02/2018, Volume 118, Issue 4, pp. 509 - 521
Background: The epidermal growth factor receptor (EGFR)-targeted therapies have been tested in the clinic as treatments for head and neck squamous cell... 
ANTIBODY | FACTOR RECEPTOR | CETUXIMAB | EGFR-targeted therapies | CANCER GENOMICS | ONCOLOGY | retinoic-acid inducible gene I | RECURRENT | EPIDERMAL-GROWTH-FACTOR | KB CELLS | interferon-alpha | EXPRESSION | PROMOTES | T-CELLS | head and neck squamous cell carcinoma | Squamous Cell Carcinoma of Head and Neck - metabolism | Interferon-alpha - pharmacology | Up-Regulation | Humans | Head and Neck Neoplasms - metabolism | Receptors, Retinoic Acid - genetics | STAT1 Transcription Factor - metabolism | Antibodies, Monoclonal, Humanized - administration & dosage | Squamous Cell Carcinoma of Head and Neck - drug therapy | Antibodies, Monoclonal, Humanized - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Drug Administration Schedule | Erlotinib Hydrochloride - administration & dosage | Head and Neck Neoplasms - drug therapy | Receptors, Retinoic Acid - metabolism | STAT1 Transcription Factor - genetics | Drug Synergism | Interferon-alpha - administration & dosage | Xenograft Model Antitumor Assays | Squamous Cell Carcinoma of Head and Neck - genetics | Animals | Erlotinib Hydrochloride - pharmacology | Cell Line, Tumor | Head and Neck Neoplasms - genetics | Mice | Transducers | Squamous cell carcinoma | Transcription factors | Epidermal growth factor receptors | Transcription | Xenotransplantation | α-Interferon | Epidermal growth factor | Rodents | Xenografts | Head and neck cancer | Interferon | Synergistic effect | Target acquisition | Stat1 protein | Tumors | Translational Therapeutics
Journal Article
BBA - Reviews on Cancer, ISSN 0304-419X, 01/2019, Volume 1871, Issue 1, pp. 29 - 39
Journal Article
Lung Cancer, ISSN 0169-5002, 2013, Volume 83, Issue 2, pp. 163 - 167
Journal Article
STEM CELLS Translational Medicine, ISSN 2157-6564, 04/2016, Volume 5, Issue 4, pp. 511 - 523
Journal Article
Breast Cancer Research (Print), ISSN 1465-5411, 07/2019, Volume 21, Issue 1, pp. 77 - 15
Journal Article
Acta Biomaterialia, ISSN 1742-7061, 01/2017, Volume 47, pp. 71 - 80
Journal Article
Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 45, pp. 73618 - 73637
Triple-negative breast cancer (TNBC) is characterized by overexpression of epidermal growth factor receptor (EGFR) and activation of its downstream signaling... 
Cytotoxicity | Epidermal growth factor receptor | Cell cycle | Anti-EGFR targeted therapy | Triple-negative breast cancer | 1ST-LINE TREATMENT | triple-negative breast cancer | cell cycle | epidermal growth factor receptor | anti-EGFR targeted therapy | BRCA1 MUTATIONS | DRUG-RESISTANCE | METASTATIC COLORECTAL-CANCER | CELL BIOLOGY | CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | TARGETED THERAPIES | RANDOMIZED PHASE-II | CETUXIMAB PLUS IRINOTECAN | GENE COPY NUMBER | cytotoxicity | Phosphorylation | Apoptosis - drug effects | Humans | Cyclins - genetics | ras Proteins - metabolism | Molecular Targeted Therapy | Triple Negative Breast Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - metabolism | Triple Negative Breast Neoplasms - pathology | Inhibitory Concentration 50 | Female | Gene Expression Regulation, Neoplastic - drug effects | Cell Survival - drug effects | Antibodies, Monoclonal - pharmacology | Protein Kinase Inhibitors - administration & dosage | Triple Negative Breast Neoplasms - genetics | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Triple Negative Breast Neoplasms - metabolism | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | G1 Phase Cell Cycle Checkpoints - drug effects | Mitogen-Activated Protein Kinases - metabolism | Life Sciences | Biomolecules | Molecular biology | Biochemistry, Molecular Biology | Genomics | Cancer
Journal Article
Acta Clinica Belgica, ISSN 1784-3286, 02/2011, Volume 66, Issue 1, pp. 10 - 17
The majority of human epithelial cancers is frequently characterized by a functional activation of the epidermal growth factor receptor (EGFR)-driven-... 
solid tumours | efficacy | EGFR targeted therapies | predictive factors | Efficacy | Predictive factors | Solid tumours | Tyrosine | Care and treatment | Epidermal growth factor | Pancreatic cancer | Lung cancer | Colorectal cancer | Monoclonal antibodies | Development and progression | Metastasis | Cancer
Journal Article
Journal Article